16413-26-6Relevant articles and documents
Development of potent and selective inhibitors targeting the papain-like protease of SARS-CoV-2
Shan, Hengyue,Liu, Jianping,Shen, Jiali,Dai, Jialin,Xu, Gang,Lu, Kuankuan,Han, Chao,Wang, Yaru,Xu, Xiaolong,Tong, Yilun,Xiang, Huaijiang,Ai, Zhiyuan,Zhuang, Guanglei,Hu, Junhao,Zhang, Zheng,Li, Ying,Pan, Lifeng,Tan, Li
, p. 855 - 9,865 (2021/05/18)
The COVID-19 pandemic has been disastrous to society and effective drugs are urgently needed. The papain-like protease domain (PLpro) of SARS-CoV-2 (SCoV2) is indispensable for viral replication and represents a putative target for pharmacological intervention. In this work, we describe the development of a potent and selective SCoV2 PLpro inhibitor, 19. The inhibitor not only effectively blocks substrate cleavage and immunosuppressive function imparted by PLpro, but also markedly mitigates SCoV2 replication in human cells, with a submicromolar IC50. We further present a convenient and sensitive activity probe, 7, and complementary assays to readily evaluate SCoV2 PLpro inhibitors in vitro or in cells. In addition, we disclose the co-crystal structure of SCoV2 PLpro in complex with a prototype inhibitor, which illuminates their detailed binding mode. Overall, these findings provide promising leads and important tools for drug discovery aiming to target SCoV2 PLpro.
3-(ureido-methyl)-4-aryl-pyridine compound, preparation method thereof and application thereof as anti-hepatoma medicament
-
Paragraph 0135; 0136; 0137, (2018/03/26)
The invention discloses a 3-(ureido-methyl)-4-aryl-pyridine compound, a preparation method thereof and application thereof as an anti-hepatoma medicament. The invention discloses a compound shown as aformula I or a pharmacologically-acceptable salt, crystal form and solvate thereof, wherein X is O or S; n is an integer of 0 to 3; R1, R2, R3, R4 and R5 are independently selected from H, cyan, COOR11, alkyl having 1 to 4 carbon atoms, alkoxy having 1 to 4 carbon atoms, trifluoromethyl, amino, nitro, hydroxyl, mercapto or halogen; R11 is selected from H or alkyl having 1 to 4 carbon atoms. Meanwhile, the invention also discloses a preparation method of the compound shown as the formula I. The compound disclosed by the invention has lower median inhibitory concentration (IC50), and a very good inhibition function on hepatoma carcinoma cells; moreover, the preparation method of the compound disclosed by the invention is simple and convenient, and has the advantages of mild reaction condition, convenience in operation and control, low energy consumption, high yield and low cost, and can be suitable for industrial production. The formula I is shown in the description.
Biological activity of analogues of YM022. Novel (3-amino substituted phenyl)urea derivatives of 1,4-benzodiazepin-2-one as gastrin/cholecystokinin-B receptor antagonists
Satoh, Masato,Okamoto, Yoshinori,Koshio, Hiroyuki,Ohta, Mitsuaki,Nishida, Akito,Akuzawa, Shinobu,Miyata, Keiji,Mase, Toshiyasu,Semple, Graeme
, p. 1412 - 1414 (2007/10/03)
A series of (3-substituted phenyl)urea analogues of the potent gastrin/cholecystokinin (CCK)-B receptor antagonist YM022 has been prepared. Structure activity relationship studies of this series suggested that a number of analogues retained good in vitro potency for gastrin/CCK-B receptor. In particular, the (3-amino substituted phenyl)urea derivatives (10-12) were more potent inhibitors of pentagastrin-induced gastric acid secretion in rats than YM022 on intraduodenal (i.d.) administration.
